Available and Suitable Myelodysplastic Syndrome Treatment Options
Myelodysplastic syndromes (MDS) are a group of cancers in which the bone marrow does not produce enough healthy blood cells. MDS mainly affects older adults, usually over the age of 60. Some signs and symptoms of MDS include fatigue, pale skin, shortness of breath, easy bruising or bleeding, and frequent or severe infections. MDS can sometimes progress to acute myeloid leukemia (AML). The exact causes of MDS are unknown, but risk factors include cigarette smoking, chemical exposure, and radiation therapy.
Myelodysplastic Syndrome Treatment: Stem Cell Transplantation
A stem cell transplant, also known as a bone marrow transplant, is currently the only potential cure for MDS. It works by replacing the patient's diseased bone marrow with healthy stem cells from a donor. Stem cells for transplantation may come from bone marrow, umbilical cord blood, or peripheral blood. There are two main types of stem cell transplants - autologous and allogeneic. In an autologous transplant, a patient's own stem cells are used. In an allogeneic transplant, stem cells are used from a donor who matches the patient's human leukocyte antigens (HLAs). Allogeneic transplants are usually considered for patients under the age of 70 with higher risk MDS. Success rates are higher for younger patients receiving transplant early in the course of the disease from a matched sibling donor.
Hypomethylating Agents
Hypomethylating agents are a class of drugs that help restore normal functioning of genes in bone marrow cells. These include azacitidine (Vidaza) and decitabine (Dacogen). They work by inhibiting DNA methyltransferase enzymes, which are involved in abnormal DNA methylation seen in MDS. Hypomethylating agents can help reduce signs and symptoms of MDS, improve blood counts, and delay the need for blood transfusions. In some cases, they may even help prevent progression to AML. Common side effects include low blood counts, nausea, vomiting, diarrhea, and fatigue. Hypomethylating agents are often prescribed for intermediate-1, intermediate-2, or high-risk MDS patients who are not eligible for stem cell transplant.
Myelodysplastic Syndrome Treatment: Immunomodulatory Drugs
Immunomodulatory drugs are another class of medications that may be used for MDS treatment. These include lenalidomide (Revlimid) and pomalidomide (Pomalyst). Their exact mechanisms are not entirely clear but they seem to enhance the immune system's ability to recognize and destroy abnormal cells. Immunomodulatory drugs have shown effectiveness in improving blood counts and response rates in some subsets of lower-risk MDS, such as those with del(5q) chromosome changes. Common side effects include low blood counts, fatigue, diarrhea, muscle aches, and rash. Immunomodulatory drugs may be used alone or in combination with other therapies.
Blood Transfusions
Blood transfusions can help manage MDS symptoms by treating anemia (low red blood cell counts) and thrombocytopenia (low platelet counts). Transfusions raise hemoglobin and platelet levels and reduce fatigue, risk of bleeding, and need for medication. However, regular transfusions carry risk of iron overload which can damage the heart, liver, and other organs. Iron chelation therapy with medications like deferasirox (Exjade) can help reduce iron levels in regularly transfused patients. Transfusions are mainly used for symptom management in patients who are not candidates for curative therapies.
Best Supportive Care
For elderly or unfit patients with MDS who cannot tolerate intensive treatments, best supportive care may be recommended. This involves managing symptoms through blood transfusions, antibiotics for infection prevention, growth factors to boost white blood cell counts, and pain medications. Supportive care aims to improve quality of life by keeping patients as active and independent as possible. It does not treat the underlying MDS but helps patients feel better and continue normal activities as long as possible.
Monitoring and Follow Up
After starting treatment for MDS, patients require frequent monitoring to check treatment response and watch for side effects or complications. Regular follow-up visits with a hematologist involve complete blood counts, physical exams, and possibly bone marrow biopsies to assess changes in cellularity and blast percentage. Monitoring blood counts often guides transfusion and medication needs. Following treatment response, some patients may be able to return to follow up every 3-6 months. Others with higher-risk disease may require closer, monthly monitoring to detect early indications of treatment failure or progression to AML. With prompt identification, alternative options can be explored in a timely manner.
Individualizing Myelodysplastic Syndrome Treatment
The optimal treatment approach for MDS depends on several factors like the subtype or risk category based on genetics, disease stage or severity, age, overall health status, and preference. Hematologists work with patients to choose the treatment best suited in their individual situation, weighing effectiveness, side effects, and sometimes even cost or access considerations. Depending on disease characteristics and response, treatment plans may utilize single or combined modality approaches. The treatment trajectory is often adjusted based on observed outcomes over time. With continuous advances, future targeted approaches hold promise to further improve survival and quality of life for MDS patients.
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.
(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/
English
Arabic
Français
Español
Português
Deutsch
Dutch
Italiano
Russian
Romaian